Sample %Recoverya± SD Proposed methods Official method Initial rate Fixed time Pure AVS t-value F-value 100.22 ± 0.14 100.31 ± 0.12 99.40 ± 0.17 1.68 1.85 1.47 2.00 Atoraz tablets (20 mg AVS/tablet)       X ± S.D.a 100.69 ± 0.17 100.86 ± 0.24 100.03 ± 0.21 t-valueb 1.72 1.07 1.85 F-valueb 1.53 1.31   Low-lip tablets (10 mg AVS/tablet)       X ± S.D.a 100.17 ± 0.23 100.31 ± 0.29 99.94 ± 0.25 t-valueb 1.49 1.55 1.79 F-valueb 1.18 1.34   Atorvast tablets (40 mg AVS/tablet)       X ± S.D.a 101.07 ± 0.19 101.17 ± 0.23 100.93 ± 0.20 t-valueb 1.79 1.49 1.27 F-valueb 1.11 1. 1. Atorvatin tablets (20 mg AVS/tablet)       X ± S.D.a 100.78 ± 0.21 101.06 ± 0.31 100.09 ± 0.26 t-valueb 2.05 1.98 1.83 F-valueb 1. 2.40   Atorvex tablets (80 mg AVS/tablet)       X ± S.D.a 101.21 ± 0.24 100.58 ± 0.21 100.98 ± 0.26 t-valueb 1.76 2.05 1.86 F-valueb 1.17 1.53   Lipolysin tablets (20 mg AVS/tablet)       X ± S.D.a 100.04 ± 0.12 100.24 ± 0.17 100.11 ± 0.14 t-valueb 1.28 0.96 1.35 F-valueb 1.36 1.47   aFive independent analyses. bTheoretical values for t and F-values at five degree of freedom and 95% confidence limit are (t=2.776) and (F=6.26).

Table 6: Application of the proposed method to the determination of AVS in tablet dosage form.